McN5652: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:McN5652.svg|McN5652 | |||
</gallery> | |||
Latest revision as of 01:11, 20 February 2025
McN5652 is a serotonin transporter inhibitor that was developed for the treatment of depression. It is a radioligand that is used in positron emission tomography (PET) imaging to visualize the serotonin transporter in the brain.
History[edit]
McN5652 was developed in the 1990s as a potential treatment for depression. However, it was not successful in clinical trials due to its poor bioavailability and rapid metabolism. Despite this, it has found use as a radioligand in PET imaging.
Use in PET Imaging[edit]
In PET imaging, McN5652 is used to visualize the serotonin transporter in the brain. This is useful in studying conditions such as depression and anxiety disorders, which are thought to be linked to abnormalities in serotonin function.
Pharmacology[edit]
McN5652 is a potent and selective inhibitor of the serotonin transporter. It binds to the transporter and prevents the reuptake of serotonin, thereby increasing the amount of serotonin available in the brain.
Side Effects[edit]
As with all drugs, McN5652 has potential side effects. These can include nausea, vomiting, and dizziness. However, these side effects are generally mild and temporary.
